

## Partner Institutions

- Institut National de la Santé et de la Recherche Médicale, INSERM (UMR 1058), Montpellier, FRANCE
- University of Bergen, NORWAY
- Centre Hospitalier Universitaire de Nantes, FRANCE
- Institut de Recherche pour le Développement, FRANCE
- Médecins Sans Frontières –Epicentre, FRANCE
- Mbarara University of Science and Technology, UGANDA
- University Teaching Hospital, Lusaka, ZAMBIA
- Hôpital National Ignace Deen, Conakry, GUINEA
- Central Hospital of Yaoundé, CAMEROON
- Pham Ngoc Thach Hospital, Ho Chi Minh City, VIETNAM
- Institut Pasteur du Cambodge, Phnom Penh, CAMBODIA
- National Centre for HIV/AIDS Dermatology and STDs, Phnom Penh, CAMBODIA



### CONTACT DATURA:


Catherine Quillet, Project manager  
[catherine.quillet@inserm.fr](mailto:catherine.quillet@inserm.fr)  
 UMR1058 – Pathogenesis & Control of Chronic and Emerging Infections  
 INSERM – 60 rue de Navacelles  
 34394 Montpellier, FRANCE

<https://datura.w.uib.no>



## Determination of Adequate **TU**berculosis Regimen in **A**dults and adolescents hospitalised with HIV-associated severe immune suppression (DATURA).

DATURA is a 48-week long, phase III, multi-centre, two-arm, open-label, randomised controlled superiority trial. It will compare the efficacy and the safety of two different TB regimens (intensified TB treatment and standard TB treatment) when given during the initial phase of treatment in HIV-infected adults and adolescents hospitalised for TB ( $CD4 \leq 100$  cells/ $\mu$ L).



This research is funded by the EDCTP2 programme (RIA2018-CO-2515). It supported by the European Union and Inserm-ANRS, and is funded by Inserm-ANRS for the Asian component. (NCT04738812)



## The DATURA Intervention

Highly immunocompromised HIV-infected individuals have an increased risk of severe TB, resulting in high fatality rates. The DATURA trial will study whether intensifying the initial phase of TB treatment will decrease mortality. The intervention will consist of initially increasing the doses of two major TB drugs (rifampicin and isoniazid) and adding corticosteroids.



**Guinea** (Hôpital national Ignace Deen Guinea)



**Uganda** (Mbarara Regional Referral Hospital)



**Vietnam** (Pham Ngoc Thach Hospital)



**Cameroon** (Hôpital Jamot Cameroon)



**Zambia** (University Teaching Hospital)




**Cambodia** (National Clinic for AIDS Dermatology and STD)



## Clinical Trial Sites

DATURA's experienced research teams will work in hospitals in Cambodia, Cameroon, Guinea, Uganda, Vietnam and Zambia. The inclusion of clinical trial sites in each of the 4 sub-Saharan African regions plus 2 South-East Asian countries, will make the results generalisable.

## Intervention Time Line



\* For detailed information about trial please see the DATURA website: <https://datura.w.uib.no>

